Tags

Type your tag names separated by a space and hit enter

[Effects of lorsartan, fosinopril on myocardial fibrosis, angiotensin II and cardiac remolding in hypertensive rats].
Hunan Yi Ke Da Xue Xue Bao. 2001 Apr 28; 26(2):118-20.HY

Abstract

OBJECTIVE

To investigate effects of lorsartan, fosinopril on myocardial fibrosis, angiotensin II and cardiac remolding in the spontaneously hypertensive rats (SHR).

METHODS

16-week-old SHRs were divided randomly into 3 groups: SHR-L (treated with lorsartan), SHR-F (treated with fosinopril) and SHR-C (untreated), each group consisting of 10 rats. After 8 weeks' and 16 weeks' therapeutic period, collagen volume fraction (CVF), perivascular circumferential area (PVCA), plasma and myocardium angiotensin II concentrations were examined by pathological examination with computed processing and radioimmunoassay respectively.

RESULTS

(1) Compared with SHR-C after 8 weeks' and 16 weeks' therapeutic period, the systolic blood pressure (SBP) was decreased similarly in both treatment groups. Heart and left ventricular weights, heart weight and eft ventricular mass indexes were lower significantly in both treatment groups than in SHR-C. Left ventricular mass index was reduced to a lower extent in SHR-F group than in SHR-L group after 16 weeks. (2) Compared with SHR-C, CVF, PVCA after 8 weeks and 16 weeks were reduced significantly in SHR-F and SHR-L. Meanwhile, CVF after 16 weeks in SHR-F than in SHR-L. (3) Compared with SHR-C after both therapeutic periods, plasma and myocardium angiotensin II concentrations were increased Significantly in SHR-L, but plasma angiotensin II concentrations were not altered significantly in SHR-F. However, myocardium angiotensin II concentrations were reduced significantly in SHR-F after 8 weeks and 16 weeks in SHR-F.

CONCLUSION

Lorsartan, fosinopril inhibit myocardial fibrosis and reverse heart hypertrophy. Fosinopril may be more effective in these above effects than Lorsartan. The mechanism of the both drug's cardioprotective effects was related to inhibition of myocardium rennin-angiotension-aldsteron system.

Authors+Show Affiliations

Department of Geriatric Cardiology, Xiangya Hospital, Central South University, Changsha 410008, China.No affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Research Support, Non-U.S. Gov't

Language

chi

PubMed ID

12536639

Citation

He, B X., et al. "[Effects of Lorsartan, Fosinopril On Myocardial Fibrosis, Angiotensin II and Cardiac Remolding in Hypertensive Rats]." Hunan Yi Ke Da Xue Xue Bao = Hunan Yike Daxue Xuebao = Bulletin of Hunan Medical University, vol. 26, no. 2, 2001, pp. 118-20.
He BX, Yu GL, Liang XQ. [Effects of lorsartan, fosinopril on myocardial fibrosis, angiotensin II and cardiac remolding in hypertensive rats]. Hunan Yi Ke Da Xue Xue Bao. 2001;26(2):118-20.
He, B. X., Yu, G. L., & Liang, X. Q. (2001). [Effects of lorsartan, fosinopril on myocardial fibrosis, angiotensin II and cardiac remolding in hypertensive rats]. Hunan Yi Ke Da Xue Xue Bao = Hunan Yike Daxue Xuebao = Bulletin of Hunan Medical University, 26(2), 118-20.
He BX, Yu GL, Liang XQ. [Effects of Lorsartan, Fosinopril On Myocardial Fibrosis, Angiotensin II and Cardiac Remolding in Hypertensive Rats]. Hunan Yi Ke Da Xue Xue Bao. 2001 Apr 28;26(2):118-20. PubMed PMID: 12536639.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Effects of lorsartan, fosinopril on myocardial fibrosis, angiotensin II and cardiac remolding in hypertensive rats]. AU - He,B X, AU - Yu,G L, AU - Liang,X Q, PY - 2003/1/23/pubmed PY - 2003/5/6/medline PY - 2003/1/23/entrez SP - 118 EP - 20 JF - Hunan yi ke da xue xue bao = Hunan yike daxue xuebao = Bulletin of Hunan Medical University JO - Hunan Yi Ke Da Xue Xue Bao VL - 26 IS - 2 N2 - OBJECTIVE: To investigate effects of lorsartan, fosinopril on myocardial fibrosis, angiotensin II and cardiac remolding in the spontaneously hypertensive rats (SHR). METHODS: 16-week-old SHRs were divided randomly into 3 groups: SHR-L (treated with lorsartan), SHR-F (treated with fosinopril) and SHR-C (untreated), each group consisting of 10 rats. After 8 weeks' and 16 weeks' therapeutic period, collagen volume fraction (CVF), perivascular circumferential area (PVCA), plasma and myocardium angiotensin II concentrations were examined by pathological examination with computed processing and radioimmunoassay respectively. RESULTS: (1) Compared with SHR-C after 8 weeks' and 16 weeks' therapeutic period, the systolic blood pressure (SBP) was decreased similarly in both treatment groups. Heart and left ventricular weights, heart weight and eft ventricular mass indexes were lower significantly in both treatment groups than in SHR-C. Left ventricular mass index was reduced to a lower extent in SHR-F group than in SHR-L group after 16 weeks. (2) Compared with SHR-C, CVF, PVCA after 8 weeks and 16 weeks were reduced significantly in SHR-F and SHR-L. Meanwhile, CVF after 16 weeks in SHR-F than in SHR-L. (3) Compared with SHR-C after both therapeutic periods, plasma and myocardium angiotensin II concentrations were increased Significantly in SHR-L, but plasma angiotensin II concentrations were not altered significantly in SHR-F. However, myocardium angiotensin II concentrations were reduced significantly in SHR-F after 8 weeks and 16 weeks in SHR-F. CONCLUSION: Lorsartan, fosinopril inhibit myocardial fibrosis and reverse heart hypertrophy. Fosinopril may be more effective in these above effects than Lorsartan. The mechanism of the both drug's cardioprotective effects was related to inhibition of myocardium rennin-angiotension-aldsteron system. SN - 1000-5625 UR - https://www.unboundmedicine.com/medline/citation/12536639/[Effects_of_lorsartan_fosinopril_on_myocardial_fibrosis_angiotensin_II_and_cardiac_remolding_in_hypertensive_rats]_ L2 - https://medlineplus.gov/highbloodpressure.html DB - PRIME DP - Unbound Medicine ER -